Physical Activity Capture Technology With Potential for Incorporation Into Closed-Loop Control for Type 1 Diabetes

Vikash Dadlani, James A. Levine, Shelly K. McCrady-Spitzer, Eyal Dassau, Yogish C Kudva

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Physical activity is an important determinant of glucose variability in type 1 diabetes (T1D). It has been incorporated as a nonglucose input into closed-loop control (CLC) protocols for T1D during the last 4 years mainly by 3 research groups in single center based controlled clinical trials involving a maximum of 18 subjects in any 1 study. Although physical activity data capture may have clinical benefit in patients with T1D by impacting cardiovascular fitness and optimal body weight achievement and maintenance, limited number of such studies have been conducted to date. Clinical trial registries provide information about a single small sample size 2 center prospective study incorporating physical activity data input to modulate closed-loop control in T1D that are seeking to build on prior studies. We expect an increase in such studies especially since the NIH has expanded support of this type of research with additional grants starting in the second half of 2015. Studies (1) involving patients with other disorders that have lasted 12 weeks or longer and tracked physical activity and (2) including both aerobic and resistance activity may offer insights about the user experience and device optimization even as single input CLC heads into real-world clinical trials over the next few years and nonglucose input is introduced as the next advance.

Original languageEnglish (US)
Pages (from-to)1208-1216
Number of pages9
JournalJournal of diabetes science and technology
Volume9
Issue number6
DOIs
StatePublished - Oct 18 2015

Fingerprint

Medical problems
Type 1 Diabetes Mellitus
Exercise
Technology
Pragmatic Clinical Trials
Organized Financing
Controlled Clinical Trials
Research
Sample Size
Glucose
Registries
Data acquisition
Head
Clinical Trials
Prospective Studies
Equipment and Supplies

Keywords

  • closed loop
  • glucose insulin
  • physical activity capture devices
  • type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Bioengineering
  • Medicine(all)
  • Biomedical Engineering

Cite this

Physical Activity Capture Technology With Potential for Incorporation Into Closed-Loop Control for Type 1 Diabetes. / Dadlani, Vikash; Levine, James A.; McCrady-Spitzer, Shelly K.; Dassau, Eyal; Kudva, Yogish C.

In: Journal of diabetes science and technology, Vol. 9, No. 6, 18.10.2015, p. 1208-1216.

Research output: Contribution to journalReview article

Dadlani, Vikash ; Levine, James A. ; McCrady-Spitzer, Shelly K. ; Dassau, Eyal ; Kudva, Yogish C. / Physical Activity Capture Technology With Potential for Incorporation Into Closed-Loop Control for Type 1 Diabetes. In: Journal of diabetes science and technology. 2015 ; Vol. 9, No. 6. pp. 1208-1216.
@article{23e69e9e8c254784851b06c0d19e7c3b,
title = "Physical Activity Capture Technology With Potential for Incorporation Into Closed-Loop Control for Type 1 Diabetes",
abstract = "Physical activity is an important determinant of glucose variability in type 1 diabetes (T1D). It has been incorporated as a nonglucose input into closed-loop control (CLC) protocols for T1D during the last 4 years mainly by 3 research groups in single center based controlled clinical trials involving a maximum of 18 subjects in any 1 study. Although physical activity data capture may have clinical benefit in patients with T1D by impacting cardiovascular fitness and optimal body weight achievement and maintenance, limited number of such studies have been conducted to date. Clinical trial registries provide information about a single small sample size 2 center prospective study incorporating physical activity data input to modulate closed-loop control in T1D that are seeking to build on prior studies. We expect an increase in such studies especially since the NIH has expanded support of this type of research with additional grants starting in the second half of 2015. Studies (1) involving patients with other disorders that have lasted 12 weeks or longer and tracked physical activity and (2) including both aerobic and resistance activity may offer insights about the user experience and device optimization even as single input CLC heads into real-world clinical trials over the next few years and nonglucose input is introduced as the next advance.",
keywords = "closed loop, glucose insulin, physical activity capture devices, type 1 diabetes",
author = "Vikash Dadlani and Levine, {James A.} and McCrady-Spitzer, {Shelly K.} and Eyal Dassau and Kudva, {Yogish C}",
year = "2015",
month = "10",
day = "18",
doi = "10.1177/1932296815609949",
language = "English (US)",
volume = "9",
pages = "1208--1216",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "6",

}

TY - JOUR

T1 - Physical Activity Capture Technology With Potential for Incorporation Into Closed-Loop Control for Type 1 Diabetes

AU - Dadlani, Vikash

AU - Levine, James A.

AU - McCrady-Spitzer, Shelly K.

AU - Dassau, Eyal

AU - Kudva, Yogish C

PY - 2015/10/18

Y1 - 2015/10/18

N2 - Physical activity is an important determinant of glucose variability in type 1 diabetes (T1D). It has been incorporated as a nonglucose input into closed-loop control (CLC) protocols for T1D during the last 4 years mainly by 3 research groups in single center based controlled clinical trials involving a maximum of 18 subjects in any 1 study. Although physical activity data capture may have clinical benefit in patients with T1D by impacting cardiovascular fitness and optimal body weight achievement and maintenance, limited number of such studies have been conducted to date. Clinical trial registries provide information about a single small sample size 2 center prospective study incorporating physical activity data input to modulate closed-loop control in T1D that are seeking to build on prior studies. We expect an increase in such studies especially since the NIH has expanded support of this type of research with additional grants starting in the second half of 2015. Studies (1) involving patients with other disorders that have lasted 12 weeks or longer and tracked physical activity and (2) including both aerobic and resistance activity may offer insights about the user experience and device optimization even as single input CLC heads into real-world clinical trials over the next few years and nonglucose input is introduced as the next advance.

AB - Physical activity is an important determinant of glucose variability in type 1 diabetes (T1D). It has been incorporated as a nonglucose input into closed-loop control (CLC) protocols for T1D during the last 4 years mainly by 3 research groups in single center based controlled clinical trials involving a maximum of 18 subjects in any 1 study. Although physical activity data capture may have clinical benefit in patients with T1D by impacting cardiovascular fitness and optimal body weight achievement and maintenance, limited number of such studies have been conducted to date. Clinical trial registries provide information about a single small sample size 2 center prospective study incorporating physical activity data input to modulate closed-loop control in T1D that are seeking to build on prior studies. We expect an increase in such studies especially since the NIH has expanded support of this type of research with additional grants starting in the second half of 2015. Studies (1) involving patients with other disorders that have lasted 12 weeks or longer and tracked physical activity and (2) including both aerobic and resistance activity may offer insights about the user experience and device optimization even as single input CLC heads into real-world clinical trials over the next few years and nonglucose input is introduced as the next advance.

KW - closed loop

KW - glucose insulin

KW - physical activity capture devices

KW - type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85021389587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021389587&partnerID=8YFLogxK

U2 - 10.1177/1932296815609949

DO - 10.1177/1932296815609949

M3 - Review article

C2 - 26481641

AN - SCOPUS:85021389587

VL - 9

SP - 1208

EP - 1216

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 6

ER -